Nucleic Acid Testing by Public Health Referral Laboratories for Public Health Laboratories Using the U.S. HIV Diagnostic Testing Algorithm
Published Date:Jan 24 2015
Source:J Clin Virol. 65:6-10.
Centers For Disease Control And Prevention (U.S.)
Nucleic Acid Amplification Techniques
Nucleic Acid Amplification Test
Referral And Consultation
Sensitivity And Specificity
Pubmed Central ID:PMC4586070
Funding:CC999999/Intramural CDC HHS/United States
U60HM000803/HM/NCHM CDC HHS/United States
Many public health laboratories adopting the U.S. HIV laboratory testing algorithm do not have a nucleic acid test (NAT), which is needed when the third-or fourth-generation HIV screening immunoassay is reactive and the antibody-based supplemental test is non-reactive or indeterminate.
Among public health laboratories utilizing public health referral laboratories for NAT conducted as part of the algorithm, we evaluated the percentage of screening immunoassays needing NAT, the number of specimens not meeting APTIMA (NAT) specifications, time to APTIMA result, the proportion of acute infections (i.e., reactive APTIMA) among total infections, and screening immunoassay specificity.
From August 2012 to April 2013, 22 laboratories enrolled to receive free APTIMA (NAT) at New York or Florida public health referral laboratories. Data were analyzed for testing conducted until June 2013.
Public health referral laboratories provide a feasible option for conducting NAT. Reducing the time from specimen collection to submission of specimens for NAT is an important step toward maximizing the public health impact of identifying acute infections.
You May Also Like: